Replimune Group Inc.

News & Events

Press Releases

In The Media

1. Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire MAY 9, 2025 4:01 PM EDT
   WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical ...
   READ ARTICLE

2. Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire APR 11, 2025 4:01 PM EDT
   WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinica...
   READ ARTICLE

3. Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire MAR 7, 2025 4:01 PM EST
   WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinica...
   READ ARTICLE

4. Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

   GlobeNewswire FEB 12, 2025 8:00 AM EST
   U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA)...
   READ ARTICLE

5. Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire FEB 7, 2025 4:01 PM EST
   WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical...
   READ ARTICLE

6. Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

   GlobeNewswire JAN 21, 2025 8:00 AM EST
   WOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a cli...
   READ ARTICLE

7. Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire JAN 10, 2025 4:01 PM EST
   WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical...
   READ ARTICLE

8. Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

   GlobeNewswire JAN 8, 2025 8:00 AM EST
   WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical...
   READ ARTICLE

9. Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

   GlobeNewswire DEC 23, 2024 8:00 AM EST
   WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical...
   READ ARTICLE

10. Replimune Announces Pricing of Upsized Public Offering

    GlobeNewswire NOV 25, 2024 11:55 PM EST
    BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical s...
    READ ARTICLE